Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease

Affiliations

¹ Department of Neurology, Psychiatry, Psychological and Brain Sciences, University of Iowa, Iowa City, IA 52242, USA; University of Iowa, Iowa City, IA 52242, USA. Electronic address: jane-paulsen@uiowa.edu.
² Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA.

Comment

Jane S Paulsen et al. Lancet Neurol. 2019 Oct.

. 2019 Oct;18(10):911-912.

doi: 10.1016/S1474-4422(19)30329-1.

¹ Department of Neurology, Psychiatry, Psychological and Brain Sciences, University of Iowa, Iowa City, IA 52242, USA; University of Iowa, Iowa City, IA 52242, USA. Electronic address: jane-paulsen@uiowa.edu.
² Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA.

No abstract available

Comment on

Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Phase 1–2a IONIS-HTTRx Study Site Teams. Tabrizi SJ, et al. N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6. N Engl J Med. 2019. PMID: 31059641 Clinical Trial.